EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Re‐Purposing Sapropterin (Kuvan) for ACTA2 ‐Related Multisystemic Smooth Muscle Dysfunction Syndrome: A Translational Mechanistic and First‐In‐Human Therapeutic Report

Moran Hausman‐Kedem, Noa Bielopolski, Vijai Krishnan, Shane Wald‐Altman, Shelly I Shrian, Omer Bar‐Yosef, Livia Kapusta, Claire Shamber, Patricia L. Musolino, Miguel Weil

Annals of Clinical and Translational Neurology · 2026-11 · 13 (11) · 2375-2381

DOI: 10.1002/acn3.70493 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Multisystemic smooth muscle dysfunction syndrome (MSMDS) is an ultra‐rare, ACTA2 ‐related disorder characterized by severe cerebrovascular disease, aortic aneurysms, and smooth muscle dysfunction. Using molecular dynamics simulations and in silico drug screening, we identified that sapropterin dihydrochloride (Kuvan) is a candidate capable of restoring p.R179H mutation disrupted actin polymerization. Patient‐derived fibroblasts demonstrated improved actin organization with Kuvan treatment. Off‐label treatment in a single pediatric patient with ACTA2 ‐MSMDS resulted in observed cerebrovascular stabilization and clinical improvement on longitudinal follow‐up. These findings provide first‐in‐human n‐of‐1 translational evidence supporting sapropterin as a potential disease‐modifying therapy for ACTA2 ‐related vasculopathies, while gene‐directed therapies are awaited. Further studies are needed to establish a robust therapeutic effect and to elucidate the mechanisms underlying the observed cerebrovascular benefit.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →